Senolytics Fail to Protect Bone From Chemotherapy-Induced Loss
A mouse study finds that senolytic drugs cannot prevent chemotherapy-driven bone loss, challenging a leading hypothesis about its cause.
20 articles
A mouse study finds that senolytic drugs cannot prevent chemotherapy-driven bone loss, challenging a leading hypothesis about its cause.
Scientists develop advanced drug delivery methods to detect and eliminate harmful senescent tumor cells that promote cancer spread.
Engineered immune cell vesicles first induce cancer cell senescence with chemo, then eliminate them with targeted senolytic drugs.
Study identifies senescent EGR1+ B cells that sabotage immunotherapy in esophageal cancer, with fisetin showing promise as a therapeutic enhancer.
Scientists uncover how SCRN1 blocks ferroptosis in liver cancer, revealing new targets for treating drug-resistant hepatocellular carcinoma.
Intratumoral senescent cells shielded by PD-L2 may explain why chemotherapy often falls short — and point to a new combination strategy.
Cambridge scientists engineer a nanoprobe that detects therapy-induced senescence non-invasively through a simple urine colorimetric test.
Researchers discover how cancer cells use lysosomes to resist RNA polymerase inhibitors and develop combination strategies to overcome this resistance.
Novel nanoparticle combines protein degrader with light therapy to reprogram cancer metabolism and eliminate breast tumors.
PQQ, a widely available dietary supplement, inhibits EZH2 and suppresses B-cell lymphoma proliferation in lab studies.
Pyrroloquinoline quinone has demonstrated anticancer activity in preclinical studies, but human cancer trials remain absent. Here's where the science stands.
Novel nanoplatform delivers copper and iron ions to trigger both ferroptosis and cuproptosis in cancer cells.
New study reveals how blocking ribosome production makes cancer cells vulnerable to ferroptosis, an iron-dependent cell death pathway.
RSL3-induced ferroptosis degrades SHP2 via chaperone-mediated autophagy, amplifying IFN-γ/STAT1 signaling and enhancing anti-PD-1 immunotherapy efficacy.
Study reveals how common cancer drugs trigger dormant tumor cells to reactivate and spread, offering new prevention strategies.
Orally bioavailable cyclin A/B RxL inhibitors exploit a cell-cycle vulnerability in small-cell lung cancer and other G1-S-checkpoint-deficient tumors.
Ginsenoside Rh4 suppresses colorectal cancer by boosting Akkermansia muciniphila and elevating protective bile acid UDCA via FXR signaling.
Two common antidepressants cause cholesterol buildup in cancer cell lysosomes, triggering immunogenic cell death that helps immune system fight tumors.
Researchers found that stopping HER2 protein degradation significantly improves trastuzumab deruxtecan cancer treatment outcomes.
New research reveals how tiny cellular packages from aging cells might be engineered to deliver targeted cancer treatments.